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Abstract
During	the	last	three	decades	lung	transplantation	(LTx)	has	become	a	proven	modality	
for	 increasing	both	survival	and	health-	related	quality	of	 life	 (HRQoL)	 in	patients	with	
various	end-	stage	lung	diseases.	Most	previous	studies	have	reported	improved	HRQoL	
shortly	after	LTx.	With	regard	to	long-	term	effects	on	HRQoL,	however,	the	evidence	is	
less	solid.	This	prospective	cohort	study	was	started	with	828	patients	who	were	on	the	
waiting	list	for	LTx.	Then,	in	a	longitudinal	follow-	up,	370	post-	LTx	patients	were	evalu-
ated	annually	for	up	to	15	years.	For	all	wait-	listed	and	follow-	up	patients,	the	following	
four	HRQoL	 instruments	were	administered:	State-	Trait	Anxiety	 Inventory,	Zung	Self-	
rating	Depression	Scale,	Nottingham	Health	Profile,	and	a	visual	analogue	scale.	Cross-	
sectional	and	generalized	estimating	equation	(GEE)	analysis	for	repeated	measures	were	
performed	 to	assess	changes	 in	HRQoL	during	 follow-	up.	After	LTx,	patients	 showed	
improvement	in	all	HRQoL	domains	except	pain,	which	remained	steady	throughout	the	
long-	term	follow-	up.	The	 level	of	anxiety	and	depressive	symptoms	decreased	signifi-
cantly	and	remained	constant.	 In	conclusion,	this	study	showed	that	HRQoL	improves	
after	LTx	and	tends	to	remain	relatively	constant	for	the	entire	life	span.
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1  | INTRODUCTION
Lung	transplantation,	with	a	reported	median	survival	of	5.8	years,	is	
currently	 recognized	 as	 a	worthwhile	modality	 of	 treatment	 for	 pa-
tients	with	 end-	stage	 lung	diseases.1	More	 than	55	000	 transplants	
have	 been	 performed	worldwide	 over	 the	 last	 three	 decades.	 This	
quantitative	increase	was	concurrent	with	improvements	in	the	physi-
cal	and	mental	aspects	of	health	in	these	patients.1,2	The	survival	rate	
has	 increased	due	to	advances	 in	surgical	 techniques	and	postoper-
ative	care	such	as	guidance	on	lifestyle	and	administration	of	potent	
antimicrobial	agents.	Besides	the	increase	in	life	years,	it	is	important	
for	 both	 patients	 and	 healthcare	 providers	 to	 assess	 the	 effects	 of	
transplantation	on	health-	related	quality	of	life	(HRQoL).
After	lung	transplantation,	patients	encounter	challenges	such	as	
risk	of	graft	rejection,	chronic	lung	allograft	dysfunction	such	as	bron-
chiolitis	obliterans	syndrome	(BOS),	infections	and	malignancies	due	
Abbreviations:	BOS,	bronchiolitis	obliterans	syndrome;	CF,	cystic	fibrosis;	CI,	confidence	interval;	COPD,	chronic	obstructive	pulmonary	disease;	EMC,	Erasmus	Medical	Center;	GEE,	generalized	
estimating	equation;	HRQoL,	health-related	quality	of	life;	LTx,	 lung	transplantation;	NHP,	Nottingham	Health	Profile;	SD,	standard	deviation;	SDS,	Zung	Self-rating	Depression	Scale;	STAI,	
State-Trait	Anxiety	Inventory;	UMCG,	,	University	Medical	Center	Groningen;	UMCU,	University	Medical	Center	Utrecht;	VAS,	visual	analogue	scale.
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to	 immunosuppression,	 and	 side	 effects	 of	 medications.3,4	 In	 both	
the	short	and	long	term	these	issues	can	also	affect	HRQoL.	Several	
studies	 have	 been	 performed	 with	 health-	outcome	 measurement	
instruments	that	capture	a	specific	element	of	HRQoL.	 In	the	short	
term,	 most	 patients	 are	 found	 to	 experience	 meaningful	 improve-
ments	 after	 lung	 transplantation.5-10	 However,	 the	 generalizability	
of	these	studies	is	constrained	by	methodological	problems	such	as	
cross-	sectional	design,	short-	term	follow-	up,	and	small	sample	sizes.	
A	 few	 longitudinal	 studies	have	evaluated	HRQoL	after	 lung	 trans-
plantation.11-14	The	 biggest	 changes	 they	 report	 occur	 in	 the	 early	
posttransplantation	 period	 in	 the	 domains	 of	 physical	 health	 and	
functioning,	like	walking	capacity,	which	generally	remained	constant	
in	 subsequent	 follow-	ups.	 But	 these	 studies	 have	 methodological	
problems	too:	small	sample	size	and	inclusion	of	combined	heart	and	
lung	 transplant	 patients.	 In	 light	 of	 their	 systematic	 review,	 Seiler	
and	 colleagues	 summarized	HRQoL	 and	 psychological	 outcomes	 in	
patients	after	 lung	 transplantation	 (LTx)	and	 found	 that	 “the	 trajec-
tory	beyond	3	years	posttransplantation	appears	to	remain	uncertain,	
mostly	due	to	the	lack	of	data.”15
In	the	present	study	we	describe	the	trend	of	HRQoL	in	a	large	
cohort	 of	 lung	 transplant	 patients	 demonstrated	 by	 longitudinal	
serial	annual	evaluations	up	to	15	years	after	transplantation.	We	
then	 evaluate	 the	 effect	 of	 demographic	 and	 clinical	 factors	 on	
that	 trend	during	 the	posttransplantation	period.	Our	hypothesis	
was	 that	 health	 improves	 after	 transplantation	 and	 then	 remains	
stable.
2  | METHODS
2.1 | Study design
In	a	prospective	cohort	study	conducted	from	1992	to	2014,	all	eli-
gible	candidates	for	lung	transplantation	at	the	University	Medical	
Center	Groningen	 (UMCG)	who	gave	 consent	 to	participate	were	
included	 in	 the	 study.	 In	 addition,	 patients	 from	 the	 University	
Medical	 Center	 Utrecht	 (UMCU)	 and	 Erasmus	 Medical	 Center	
Rotterdam	(EMC)	were	included	from	2002	onward.	Inclusion	crite-
ria	were	candidacy	for	lung	transplantation,	age	≥18,	and	sufficient	
Dutch	 language	 skills.	 Neither	 patients	 with	 previous	 lung	 trans-
plantation	nor	candidates	for	a	combined	heart	and	lung	or	lung	and	
liver	transplantation	were	included.
The	study	protocol	was	approved	by	the	institutional	review	boards	
of	 all	 3	 centers.	 Because	 posttransplantation	 health	 evaluations	 are	
part	of	standard	care	at	all	3	centers,	Dutch	legislation	did	not	require	
ethical	approval.	The	immunosuppression	protocol	in	the	UMCG	was	
cyclosporine	based	from	1992	to	2001;	afterwards,	it	was	tacrolimus	
based.	All	participants	received	adequate	information	about	the	study	
and	were	 assured	 that	 their	 information	would	 remain	 confidential.	
After	we	obtained	 informed	consent,	demographic	variables	such	as	
age,	gender,	marital	status,	working	situation,	and	underlying	pulmo-
nary	disease	were	registered.
All	patients	were	asked	to	fill	in	2	generic	and	2	domain-	specific	in-
struments	to	score	their	perceived	HRQoL.	The	self-	report	instruments	
were	first	completed	upon	entering	the	waiting	list	for	lung	transplan-
tation	and	 subsequently	upon	annual	 evaluation.	The	maximum	 fol-
low-	up	time	 in	 this	cohort	was	15	years.	Forms	were	sent	by	postal	
mail	and	participants	were	asked	to	fill	in	the	instruments	themselves	
at	home.
2.2 | HRQoL instruments
This	study	applied	2	domain-	specific	HRQoL	instruments	to	evaluate	
anxiety	 and	depression.	Anxiety	was	measured	with	 the	State-	Trait	
Anxiety	 Inventory	 (STAI),	 a	 20-	item	 self-	report	 measure	 in	 which	
responses	 are	 given	 on	 a	 4-	point	 Likert	 scale	 from	 4	 (always)	 to	 1	
(never).	The	overall	score	ranges	from	20	to	80,	with	80	representing	
the	worst	possible	state	of	anxiety.16	Depression	was	measured	with	
the	 Zung	 Self-	rating	 Depression	 Scale	 (SDS),	 a	 20-	item	 self-	report	
instrument	with	a	4-	point	Likert	scale	used	to	evaluate	the	psycho-
logical,	affective,	and	somatic	symptoms	associated	with	depression.	
The	overall	score	to	be	obtained	with	this	instrument	ranges	from	25	
to	100,	where	high	scores	indicate	severe	symptoms.17	We	followed	
the	 standard	 instructions	 of	 the	Zung	 and	STAI.	Accordingly,	when	
calculating	overall	scores,	if	the	number	of	missing	items	was	equal	or	
less	than	2,	we	imputed	their	value	by	taking	the	mean	of	the	other	
items.	Overall	scores	with	more	than	2	missing	items	were	excluded	
from	the	analysis.
In	addition,	 the	Nottingham	Health	Profile	 (NHP)	was	used	as	a	
generic	HRQoL	instrument.	The	NHP	is	a	self-	report	tool	that	contains	
38	items	and	measures	6	domains	of	HRQoL:	emotional	reactions,	so-
cial	isolation,	sleep,	pain,	energy,	and	physical	mobility.	The	response	
categories	for	each	 item	are	“yes”	and	“no.”	Separate	scores	are	cal-
culated	for	each	domain	and	lie	between	0	and	100,	whereby	higher	
scores	represent	lower	levels	of	HRQoL.	Following	the	instructions	for	
this	instrument,	if	for	an	individual	patient	a	response	was	missing	on	
at	least	one	item,	that	domain	was	excluded	from	the	analysis.18
In	addition,	patients	were	shown	the	visual	analogue	scale	of	the	
EuroQol	instrument	(EQ-	VAS)	and	asked	to	choose	a	number	between	
0	and	100	to	represent	their	perceived	health	condition.	A	higher	num-
ber	indicates	better	health.19
2.3 | Statistical analysis
Descriptive	 statistics	 were	 used	 to	 summarize	 the	 patients’	 demo-
graphic	and	baseline	characteristics.	Means	(standard	deviations,	SDs)	
were	calculated	at	every	follow-	up	point	to	chart	the	trends	for	the	
HRQoL	domains.	Several	independent	variables	were	selected	on	the	
basis	 of	 their	 clinical	 relevance	 and	 similar	 previous	 studies	 for	 the	
purpose	of	 assessing	 their	 effect	on	 the	 trends	of	HRQoL	 found	 in	
this	study.	The	list	consisted	of	gender,	age,	working	situation,	marital	
status,	 pretransplantation	diagnosis,	 type	of	 transplant,	 and	 type	of	
immunosuppression	after	transplantation.	The	independent	variables	
were	entered	in	the	analysis	as	determinants	of	longitudinal	change.	
Separate	analyses	were	performed	in	which	the	patients	were	divided	
in	3	groups	based	on	age	(younger	than	44,	between	45	and	55,	and	
56	 or	 older).	 Graphs	 were	 drawn	 to	 demonstrate	 the	 trend	 of	 the	
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scores	of	the	instruments	with	a	95	percent	confidence	interval	(CI).	
The	scores	were	reversed	on	the	graphs	to	demonstrate	the	increas-
ing	trend	of	HRQoL.
Generalized	estimating	equation	(GEE)	models	were	employed	to	
identify	 significant	 determinants	 of	 longitudinal	 changes	 in	 HRQoL	
during	the	15-	year	follow-	up	time.	GEE	analysis	takes	into	account	the	
correlation	of	responses	for	an	individual	patient	and	has	many	advan-
tages	for	analyzing	longitudinal	or	repeated	measures.	This	statistical	
routine	is	flexible	in	handling	missing	data	and	produces	efficient	and	
unbiased	regression	coefficients	(β).20	In	this	study,	the	exchangeable	
working	correlation	matrix	option	was	used	 to	estimate	βs	 for	each	
independent	variable.	Level	of	significance	was	set	at	a	P value of less 
than	0.05.	Student’s	t-	tests	were	performed	to	compare	the	results	of	
our	study	with	data	for	the	general	population.	All	statistical	analyses	
were	done	with	 the	SPSS	20.0	software	package	 (IBM	Corporation,	
Chicago,	 IL).	SigmaPlot	version	12.3	 (Systat	Software,	 Inc.,	San	Jose,	
CA)	was	used	for	drawing	the	graphs.
3  | RESULTS
3.1 | Patients’ participation and demographics
From	 1992	 to	 2014	 a	 total	 of	 1083	 patients	 with	 end-	stage	 lung	
disease	 became	 candidates	 for	 lung	 transplantation	 in	 the	 UMCG,	
UMCU,	and	EMC.	Among	them	828	(76%)	participated	in	the	study	by	
filling	in	the	instruments	the	moment	they	were	placed	on	the	wait-
ing	list.	Some	possible	reasons	for	not	participating	in	the	study	were	
a	 lack	of	 interest,	a	short	 time	between	candidacy	and	surgery,	and	
being	too	ill.	Eventually,	370	(34%)	of	those	initial	participants	under-
went	 lung	 transplantation.	 In	addition	 to	 those	828	participants,	56	
patients	(from	the	original	1083	candidates)	filled	in	the	instruments	
after	 transplantation	 for	 the	 first	 time,	bringing	 the	 total	number	of	
participants	up	 to	884	 (81%).	Figure	1	 schematically	depicts	 the	 in-
clusion	 and	 the	 number	 of	 patients	 (including	 percentages	 of	 living	
respondents)	who	filled	in	the	HRQoL	instruments	at	each	time	point,	
the	number	of	patients	who	died,	were	censored	due	to	the	end	of	
study,	and	were	lost	to	follow-	up	during	the	15	years.	The	age	of	pa-
tients	 in	this	study	ranged	from	13	to	69	years,	with	a	mean	age	of	
46.6	(11.7	SD)	when	waitlisted.	Two	patients	were	registered	on	the	
waiting	 list	 at	 age	 13	 and	 14,	 but	 they	 started	 to	 fill	 in	 the	 instru-
ments	after	they	turned	18.	A	total	of	487	patients	(55%)	were	female	
(Table	1).	 A	 large	 proportion	 of	 the	 participants	 (30%)	 had	 become	
end-	stage	lung-	disease	patients	due	to	chronic	obstructive	pulmonary	
disease	(COPD),	and	a	smaller	share	due	to	cystic	fibrosis	(CF)	(17%).
3.2 | Baseline differences in HRQoL
In	 the	waiting	 list	 assessment,	 female	 patients	 showed	 significantly	
higher	levels	of	anxiety	and	depression	than	male	patients	(Figure	2).	
Their	 mean	 NHP	 scores	 on	 energy	 and	 physical	 activity	 were	 also	
worse	(Figure	3).	Patients	who	were	working	or	studying	had	signifi-
cantly	better	STAI	and	Zung	scores	 (38.3	±	0.8	and	50.6	±	0.6)	 than	
the	nonworking	group	on	the	waiting	list	(43.2	±	0.5	and	55.7	±	0.4).	
Those	working	or	studying	had	better	scores	on	energy,	social	isola-
tion,	 and	 physical	 activity	 (52.34	±	5.3,	 8.90	±	2.3,	 and	 35.74	±	3.1)	
compared	 to	 the	 nonworking	 group	 (72.21	±	2.7,	 14.62	±	1.6,	 and	
55.89	±	2.2).	Similarly,	the	working	or	studying	patients	reported	bet-
ter	VAS	scores	before	the	transplantation	compared	to	patients	who	
did	not	work	or	study	(51.1	±	2.4	and	41.4	±	1.5).
According	to	the	underlying	medical	disease,	patients	with	CF	had	
the	lowest	level	of	anxiety	(39.1	±	0.9),	followed	by	patients	diagnosed	
with	alpha	1-	antitrypsin	deficiency	(40.5	±	1).	Patients	with	COPD	had	
the	highest	STAI	mean	score	(43.9	±	0.7).	They	also	had	significantly	
higher	 levels	of	depression	 (56.7	±	0.6)	 than	patients	with	CF,	 alpha	
1-	antitrypsin	 deficiency,	 and	 other	 pulmonary	 diseases	 (52.8	±	0.8,	
53	±	0.8,	and	54.1	±	0.5,	respectively).
3.3 | Patterns of HRQoL after LTx
The	STAI	and	Zung	mean	scores	as	well	as	all	domains	of	the	NHP,	
except	 for	 pain,	 declined	 sharply	 immediately	 after	 transplantation.	
Overall,	 the	 study	 population	 reported	 a	 considerably	 higher	 per-
ceived	 health	 condition	 (VAS	 score)	 compared	 to	 the	 assessment	
when	placed	on	the	waiting	list	(Table	2).	The	improvement	in	HRQoL	
remained	 relatively	 steady	 from	 the	 first	 year	 after	 LTx	 to	 the	 end	
of	follow-	up.	After	transplantation,	most	patients	reported	an	HRQoL	
comparable	to	that	of	the	general	population.21	However,	posttrans-
plantation	 patients	 had	 a	 higher	 level	 of	 depression	 compared	 to	
	values	for	the	general	population	sample	(P < .001).17
3.4 | Patterns of HRQoL after LTx in different groups
GEE	analysis	was	performed	to	evaluate	the	longitudinal	differences	
in	HRQoL	scores	on	select	independent	variables	(Appendices	1	and	
2).	 Regarding	 gender,	 females	 showed	 significantly	 higher	 levels	 of	
depression	than	males	after	LTx	(P = .01)	(Figure	2).	Similarly,	females	
had	worse	mean	scores	on	energy	level	(P = .009)	and	physical	activity	
(P = .012)	(Figure	3).	Regarding	age,	patients	in	all	3	categories	showed	
a	significant	decline	in	anxiety	and	depressive	symptoms	immediately	
after	transplantation,	and	that	trend	continued	steadily	until	the	end	
of	follow-	up.	Patients	younger	than	44	years	had	significantly	better	
scores	on	sleep	(P = .011)	and	physical	activity	(P = .0001).
From	the	first	to	the	fourth	year	after	transplantation,	the	lowest	
STAI	scores	were	found	among	cystic	fibrosis	patients	and	the	high-
est	 among	 COPD	 patients.	 However,	 GEE	 analysis	 did	 not	 show	 a	
significant	difference	between	these	diagnostic	groups.	A	comparison	
of	 the	4	diagnostic	 groups	 showed	 that	patients	with	CF	and	alpha	
1-	antitrypsin	 deficiency	 had	 significantly	 lower	 levels	 of	 depression	
(P = .003	 and	 P = .025,	 respectively)	 than	 patients	 with	 other	 di-
agnoses.	The	perception	of	overall	 health	was	better	 in	 the	CF	 and	
alpha	 1-	antitrypsin	 groups,	 according	 to	 their	 VAS	 score	 (P = .001 
and P = .016).	CF	patients	also	had	the	lowest	scores	on	energy	level	
(P = .007),	sleep	(P = .001),	and	physical	activity	(P < .001).
The	 STAI	 and	 Zung	mean	 scores	 of	 both	working/studying	 and	
nonworking	groups	decreased	considerably	1	year	after	the	transplan-
tation	and	remained	constant	during	the	posttransplantation	period.	
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F IGURE  1 Scheme	of	study	inclusion	
and	follow-	up	(LTx,	lung	transplantation)
Total LTx candidates
N=1083
Pre LTx assessment
N=828
N=320
100%
N=266
94%
N=214
84%
N=180
80%
N=161
76%
N=123
63%
N=106
60%
N=85
52%
N=63
44%
N=54
40%
N=43
34%
N=31
28%
N=27
25%
N=22
21%
N=12
13%
Waiting list
assessment
1 year after LTx
2 years after LTx
3 years after LTx
4 years after LTx
5 years after LTx
6 years after LTx
7 years after LTx
8 years after LTx
9 years after LTx
11 years after LTx
10 years after LTx
13 years after LTx
12 years after LTx
15 years after LTx
14 years after LTx
End of follow-up
N=56 Post LTx inclusion
N=90 died
N=420 did not receive LTx
N=54 lost to follow-up
N=15 died
N=22 censored
N=17 lost to follow-up
N=18 died
N=11 censored
N=23 lost to follow-up
N=16 died
N=13 censored
N=5 lost to follow-up
N=10 died
N=4 censored
N=5 lost to follow-up
N=9 died
N=8 censored
N=21 lost to follow-up
N=14 died
N=3 censored
N=0 lost to follow-up
N=8 died
N=7 censored
N=6 lost to follow-up
N=12 died
N=6 censored
N=4 lost to follow-up
N=9 died
N=0 censored
N=0 lost to follow-up
N=7 died
N=4 censored
N=0 lost to follow-up
N=5 died
N=7 censored
N=0 lost to follow-up
N=4 died
N=0 censored
N=0 lost to follow-up
N=3 died
N=2 censored
N=0 lost to follow-up
N=8 died
N=2 censored
N=0 lost to follow-up
Percentages in central row represent the proportion of living patients that were not censored
and filled in the instruments.
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The	working/studying	group	had	a	statistically	significant	lower	level	
of	anxiety	(P = .024)	and	depression	(P = .016).	This	group	also	had	bet-
ter	scores	in	the	physical	activity	and	pain	domains	of	NHP	(P < .001),	
especially	in	the	first	6	years	of	the	posttransplantation	period.
Patients	 who	 received	 tacrolimus	 for	 immunosuppression	 after	
lung	transplantation	reported	levels	of	anxiety	in	our	study	compara-
ble	to	those	reported	by	patients	who	received	cyclosporine	(P = .953).	
Because	the	use	of	tacrolimus	is	part	of	the	newest	protocol	for	pa-
tients	in	our	medical	centers,	the	comparison	of	these	groups	is	only	
possible	 for	 the	most	 recent	11	years.	According	 to	 the	depression,	
despite	the	slightly	higher	level	of	depressive	symptoms	in	the	tacro-
limus	group	compared	to	the	cyclosporine	group	 in	 the	first	3	years	
after	LTx,	GEE	analysis	did	not	show	a	statistically	significant	difference	
	between	these	two	groups	during	the	posttransplantation	period.
Regarding	the	type	of	transplant,	unilateral	and	bilateral	 lung	re-
cipients	showed	a	similar	steady	trend	in	STAI	and	Zung	scores	during	
follow-	up.	 Patients	who	 underwent	 unilateral	 transplantation	 had	 a	
better	score	for	pain	than	the	bilateral	group	in	the	first	year	after	sur-
gery.	This	difference	was	not	significant	during	subsequent	years	and	
both	groups	showed	a	steady	trend	over	time.	In	addition,	there	was	
no	statistically	significant	difference	in	other	domains	between	these	
two	groups.	Unilateral	transplant	patients	had	worse	VAS	scores,	with	
an	increasing	trend	during	the	first	4	posttransplantation	years	com-
pared	to	the	bilateral	recipients.	The	score	of	both	groups	became	sim-
ilar	in	the	fifth	year	and	remained	constant	until	the	end	of	follow-	up.
4  | DISCUSSION
The	main	goal	of	this	study	was	to	describe	the	long-	term	HRQoL	of	
lung	 transplant	 recipients	 up	 to	 15	years	 after	 surgery.	 Lung	 trans-
plantation	 is	 performed	 in	 chronic,	 end-	stage	 lung	 disease	 patients	
who	are	 at	high	 risk	of	death	 (>50%)	within	2	years	without	 trans-
plantation.22	These	chronic	diseases	considerably	reduce	the	patients’	
HRQoL.	Previous	studies	have	shown	that	the	most	noteworthy	im-
provements	in	HRQoL	happen	during	the	first	year	after	transplanta-
tion.11,12	In	our	study,	we	also	found	that	most	improvement	occurred	
within	 the	 first	 year	 in	 the	main	domains	of	HRQoL	 (psychological,	
social,	and	physical)	except	for	the	pain	domain	of	NHP,	which	stayed	
constant	during	the	whole	study	period.	This	finding	was	predictable,	
TABLE  1 Sociodemographic	characteristics	of	the	study	
population
Characteristics N Percent
Waiting	list
Gender
Male 397 44.9
Age	years,	mean	(range) 46.6 13-	69
Marital	status	(have	partner) 599 67.8
Working	or	studying 215 24.3
Underlying	medical	disease
Alpha	1-	antitrypsin	deficiency 109 12.3
Cystic	fibrosis 155 17.5
COPD 269 30.4
Other 351 39.7
First	year	after	LTx
Gender
Male 154 48.1
Age	years,	mean	(range) 47.6 19-	66
Marital	status	(have	partner) 213 66.6
Working	or	studying 76 23.8
Underlying	medical	disease
Alpha	1-	antitrypsin	deficiency 55 17.2
Cystic	fibrosis 48 15.0
COPD 97 30.3
Other 120 37.5
Type	of	LTx
Bilateral 199 62.2
Type	of	immunosuppression
Tacrolimus 225 70.3
F IGURE  2 Reversed mean scores for 
depressive	symptoms	(Zung)	by	gender
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in	view	of	the	improvement	in	lung	function	during	the	posttransplan-
tation	period.	Constant	use	of	immunosuppressive	drugs	after	trans-
plantation,	 as	 well	 as	 the	 risk	 of	 many	 immunosuppression-	related	
health	problems	like	various	cancers	and	infectious	diseases,	but	also	
side	 effects	 such	 as	 headache,	 nausea,	 tremor,	 and	 vomiting,3,23,24 
might	 in	the	long-	term	lead	to	a	decrease	in	the	health	condition	of	
the	lung	recipients.
One	of	the	important	findings	of	this	study	was	that	the	improve-
ments	in	the	patients’	health	condition	fall	largely	within	the	reference	
values	 of	 the	 general	 population	 and	 remain	 almost	 steady	 during	
the	next	15	years.	This	finding	also	has	been	observed	previously	 in	
a	study	by	Kugler	and	colleagues.25	 In	a	cohort	of	280	LTx	patients,	
they	found	an	overall	improvement	in	perceived	HRQoL	that	brought	
HRQoL	to	a	level	comparable	to	that	of	a	cohort	of	healthy	controls.	
Kugler	 and	 colleagues	 found	 a	 decline	 in	HRQoL	5	 to	 6	years	 after	
transplantation	exclusively	among	a	subgroup	of	patients	with	BOS.	
Some	previous	studies	evaluated	the	health	status	of	lung	transplant	
candidates	more	than	1	year	after	transplantation	and	reported	a	de-
cline	in	health	status.12,	26-28	However,	at	a	duration	of	4	to	10	years,	
the	follow-	up	period	in	these	studies	was	relatively	short	in	compari-
son	with	our	study.
Another	 finding	 of	 our	 study	 is	 that	 female	 patients	 generally	
had	 relatively	worse	 HRQoL	 both	 before	 and	 after	 transplantation.	
However,	 both	 genders	 showed	 significant	 improvement	 in	HRQoL	
afterward.	The	worse	HRQoL	 among	 females	was	 predominantly	 in	
the	physical	domains	of	 the	NHP,	 concurring	with	 findings	 for	both	
healthy	people	and	populations	with	chronic	lung	diseases	in	previous	
studies.21,	29-33	According	to	those	studies,	this	difference	in	HRQoL	is	
not	related	to	the	difference	in	the	severity	of	the	symptoms	between	
males	and	females.	The	 lower	HRQoL	among	females	may	be	partly	
explained	 by	 the	 different	 prevalence	 of	 mobility-	related	 disease	
among	males	and	females.	Musculoskeletal	disorders	and	movement	
TABLE  2 Scores	on	the	4	HRQoL	instruments:	mean	(standard	deviation)
Reference 
value MID
Waiting list 
N = 828 Year 1 N = 320 Year 5 N = 161 Year 10 N = 54 Year 15 N = 12
STAI ≤37 10 42.1	(11.2) 32.9	(10.8) 33.4	(10.4) 33.4	(10.9) 36.0	(14.0)
Zung ≤33 8-	9 54.5	(9.5) 41.8	(10.9) 43.0	(10.4) 41.8	(10.5) 43.1	(10.6)
NHP	Energy <15 n/a 67.5	(35.6) 14.3	(29.9) 17.4	(31.7) 17.5	(30.9) 29.4	(45.9)
NHP	Pain <15 n/a 8.3	(17.7) 7.4	(18.4) 9.1	(22.5) 16.0	(29.4) 16.4	(30.7)
NHP	Emotional	
reactions
<15 n/a 18.3	(21.4) 6.0	(13.4) 6.8	(14.7) 8.6	(18.4) 11.9	(20.0)
NHP	Sleep <15 n/a 25.4	(29.8) 16.4	(26.4) 15.7	(25.4) 18.7	(29.1) 3.5	(11.0)
NHP	Social	isolation <15 n/a 13.2	(19.5) 3.2	(9.7) 2.9	(9.0)	 4.8	(13.4) 6.1	(10.4)
NHP	Physical	mobility <15 n/a 51.0	(26.5) 11.1	(19.8) 11.1	(18.3) 13.6	(18.2) 10.0	(15.7)
VAS >82 7-	10 43.7	(18.5) 78.5	(16.8) 77.7	(17.4) 77.8	(15.5) 74.7	(21.9)
Range	of	possible	scores:	STAI,	20	to	80;	Zung,	25	to	100;	NHP,	0	to	100;	and	VAS,	0	to	100.
MID,	minimal	important	difference.
F IGURE  3 Reversed mean scores for 
physical	activity	and	energy	domains	of	
HRQoL	(NHP)	by	gender
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impairments	are	more	prevalent	in	women.34,	35	Moreover,	some	stud-
ies	indicate	that	women	may	have	higher	expectations	of	medical	care	
and	are	less	satisfied	than	men	after	receiving	the	same	treatment.36-38 
Similarly,	women	might	have	higher	expectations	of	lung	transplanta-
tion	than	men	and	would	expect	to	resume	their	social	and	physical	
activities	 sooner.	Holding	 higher	 expectations	might	 be	 a	 source	 of	
distress	 and	 cause	more	 anxiety	 and	 depressive	 symptoms.	 Further	
research	with	regard	to	the	causal	 relation	between	expectations	of	
transplant	 outcomes,	 gender,	 and	 mental	 state	 might	 be	 helpful	 in	
	delivering	more	personalized	care	in	the	future.
In	this	study,	patients	with	CF	generally	reported	better	perceived	
HRQoL	than	other	patients.	Comparison	to	other	patients	showed	that	
the	CF	patients	experienced	fewer	problems	with	mobility	and	sleep.	
This	finding	is	in	line	with	the	results	of	previous	studies	regarding	the	
influence	of	baseline	diagnosis	on	HRQoL	after	 transplantation.39-42 
Due	to	a	lifetime	of	lung	disease	before	LTx,	the	CF	patients	could	not	
experience	the	“full”	health	that	other	groups	of	patients	could	have	
enjoyed	in	earlier	stages	of	life.	After	LTx,	they	could	enjoy	a	lifestyle	
free	of	 respiratory	symptoms,	which	 is	 indeed	a	 reason	 for	a	higher	
HRQoL.	Moreover,	Patients	with	CF	are	younger	than	other	patients	at	
the	time	of	LTx	and	generally	in	better	physical	condition.	In	addition,	
engaging	in	more	diverse	activities	than	older	patients	do,	such	as	re-
turning	to	work	or	study,	can	have	a	positive	effect	on	their	perceived	
HRQoL.
The	 overall	 health	 condition	 of	 patients	who	worked	 or	 studied	
was	better	than	that	of	the	nonworking	group,	both	before	and	after	
transplantation.	 This	 difference	was	 pronounced	 in	 the	 psychologi-
cal	 and	 social	 domains	 of	HRQoL.	The	 relationship	 between	having	
a	job	and	a	better	perceived	HRQoL	was	also	found	in	previous	stud-
ies	in	the	general	population43,	44	and	other	patient	populations.45,	46 
Employment	is	important	to	the	patients,	as	it	provides	them	with	an	
income,	opportunities	to	structure	their	daily	lives,	and	satisfying	so-
cial	interactions,	all	of	which	can	affect	HRQoL.	This	finding	suggests	
that	working	after	transplantation	might	help	increase	the	HRQoL	of	
patients.
By	extending	the	duration	of	follow-	up,	the	present	study	makes	
an	important	contribution	to	the	body	of	literature.	Previous	studies	
reported	discrepancies	 in	 the	 long-	term	trend	of	HRQoL	among	pa-
tients	 after	 transplantation,	 but	 those	 studies	 followed	 patients	 for	
only	 a	 few	 years	 or	 used	 a	 retrospective	 study	 design.	 Due	 to	 the	
multicenter	 approach,	 our	 prospective	 longitudinal	 study	with	 long-	
term	posttransplantation	follow-	up,	a	relatively	large	sample	size,	and	
homogeneity	of	the	cases	regarding	single	or	combined	organ	trans-
plantation,	the	results	of	our	study	add	valuable	knowledge	to	the	field	
and	can	be	used	as	strong	evidence	for	the	long-	term	effectiveness	of	
lung	 transplantation	with	 regard	 to	HRQoL.	We	used	2	generic	and	
2	 domain-	specific	 HRQoL	 instruments	 to	 evaluate	 most	 aspects	 of	
the	health	condition	in	our	population.	When	this	study	was	started	
in	1992,	NHP	was	one	of	the	most	well-	known	instruments	to	eval-
uate	 the	 health	 condition	 of	 patients.	Although	 this	 instrument	 has	
been	applied	less	frequently	in	recent	years,	we	decided	to	continue	
using	 it	 for	the	 latest	evaluations	to	ensure	uniformity	 in	the	results	
of	 the	study.	By	using	 these	4	 instruments	we	covered	most	of	 the	
psychological	and	social	as	well	as	some	or	 the	physical	domains	of	
HRQoL,	which	increased	the	reliability	of	the	results.
Despite	 the	 remarkable	 strength	 of	 this	 study,	 few	 limitations	
were	nonavoidable.	A	well-	known	challenge	in	long-	term	studies	is	
reducing	loss	to	follow-	up.	The	response	rate	among	the	living	lung	
transplant	recipients	after	10	years	 in	our	study	was	25.8%,	which	
is	relatively	low.	We	performed	some	additional	analyses	to	prevent	
possible	 bias	 due	 to	 a	 large	 number	 of	missing	 patients.	 First	we	
evaluated	 the	 demographic	 characteristics	 of	 patients	 who	 were	
censored	due	to	the	end	of	the	study,	lost	to	follow-	up,	or	had	died	
and	compared	these	with	a	profile	of	 the	 included	patients.	There	
were	 no	 salient	 differences	 in	 demographics	 between	missed	 pa-
tients	and	ongoing	participants	at	specific	follow-	up	time	points.	We	
also	 compared	 the	 final	 assessment	 of	 HRQoL	 scores	 of	 patients	
who	were	censored,	lost	to	follow-	up,	or	had	died	with	the	scores	of	
respondents	who	were	still	participating	in	the	study	at	certain	time	
points	(Appendix	3).	Again,	no	particular	differences	were	found	be-
tween	the	two	groups.	The	total	number	of	patients	who	were	lost	
to	follow-	up	after	transplantation	without	a	known	reason	was	only	
81	(25%).	Due	to	the	death	registry	of	the	participating	hospitals	we	
discerned	that	merely	7	of	these	patients	died	after	they	were	lost	to	
follow-	up;	median	survival	after	last	assessment:	2	years	(interquar-
tile	range	[IQR]	1-	4	years).	Accordingly,	most	patients	who	were	lost	
to	follow-	up	were	still	alive	during	the	time	of	the	study	(range	until	
end	of	the	study	1	to	5	years,	median	3	years	[IQR	1-	4	years]).	Thus	
the	incidence	of	major	posttransplantation	complications	with	high	
mortality	rate	is	limited	among	these	patients.	Therefore,	we	can	at	
least	conclude	that	there	is	no	large	systematic	bias	due	to	missing	
patients.
Another	 limitation	of	this	study	is	that	 it	 lacks	a	control	group.	
Having	 one	 would	 have	 enabled	 a	 more	 thorough	 evaluation	 of	
confounding	 variables	 like	 aging	 and	 social	 changes	 during	 the	
follow-	up	period.	A	potential	 limitation	 is	 the	use	of	 conventional	
self-	report	 instruments	 to	 score	 perceived	 HRQoL.	 These	 instru-
ments	may	be	susceptible	 to	so-	called	adaptation	 in	chronically	 ill	
patients.47	Moreover,	NHP	has	limited	ability	to	detect	respiratory-	
related	impacts	on	perceived	HRQoL.	Finally,	in	this	study	we	exam-
ined	 important	baseline	characteristics	 that	can	affect	 the	HRQoL	
of	patients	long	term	after	LTx.	Based	on	the	research	data	we	col-
lected,	we	are	not	in	the	position	to	study	the	relationship	of	these	
factors	 and	 particular	 posttransplantation	 factors	 (eg,	 BOS	 and	
chronic	heart	failure)	by	extending	the	analyses.	Further	studies	are	
necessary	to	assess	the	causal	pathways	of	these	factors	in	HRQoL	
alteration.
In	conclusion,	in	line	with	previous	studies,	this	study	showed	that	
lung	 transplant	 patients	 experience	 improvement	 in	 all	 domains	 of	
HRQoL	within	the	first	year	after	transplantation.	Despite	differences	
in	 survival	 and	 posttransplantation	 immunosuppression	 treatment,	
their	perceived	 improvement	 tends	to	 remain	relatively	constant	 for	
the	entire	life	span.	This	positive	effect	over	such	a	long	period	of	fol-
low-	up	is	reported	here	for	the	first	time,	convincingly	demonstrating	
the	long-	term	effectiveness	of	this	treatment	modality	in	patients	with	
end-	stage	lung	diseases.
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APPENDIX 1
I N D E P E N D E N T  D E T E R M I N A N T S  O F  L O N G I T U D I N A L  C H A N G E S  I N  S T A I ,  Z U N G ,  A N D  V A S  S C O R E S
STAI Zung VAS
Estimate (SE) P Value Estimate (SE) P Value Estimate (SE) P Value
Gender
Male −2.077	(1.19) .081 −3.149	(1.23) .011 2.409	(1.89) .202
Working −2.972	(1.32) .024 −3.196	(1.32) .016 3.220	(1.99) .106
Underlying	medical	disease
Alpha	
1-	antitrypsin	
deficiency 
−1.297	(1.70) .445 −3.876	(1.73) .025 6.761	(2.80) .016
COPD 1.110	(1.49) .457 0.688	(1.52) .650 1.128	(2.38) .636
CF −3.071	(1.58) .051 −5.321	(1.78) .003 7.915	(2.40) .001
Age	groups
Young −2.129	(1.61) .186 −2.902	(1.70) .087 3.876	(2.74) .157
Middle-	aged −1.182	(1.67) .479 −2.211	(1.63) .176 0.611	(2.73) .823
Married −0.236	(1.53) .878 −1.071	(1.50) .476 1.455	(2.32) .531
Type	of	immunosuppression
Tacrolimus 0.75	(1.26) .953 2.085	(1.33) .119 0.845	(2.13) .692
Variables	considered	in	the	GEE	models:	gender,	working	situation,	underlying	medical	disease,	age,	marital	status,	and	immunosuppression	after	
LTx.	SE,	standard	error.
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APPENDIX 3
D I F F E R E N C E  I N  M E A N  S C O R E S  O F  P A T I E N T S  T H A T  D R O P P E D  O U T  A N D  R E S P O N D E N T S  O N  T H E  4  H R Q O L 
INSTRUMENTS :  D IFFERENCE  OF  MEAN  (P  VALUE )
2nd year dropouts N = 54 5th year dropouts N = 19 10th year dropouts N = 9 15th year dropouts N = 10
STAI 1.8	(0.30) 5.1	(0.13) 3.2	(0.45) −0.9	(0.83)
Zung 3.5	(0.07) 3.1	(0.31) 5.9	(0.16) 2.8	(0.57)
NHP	Energy 9.5	(0.07) 12.1	(0.20) 28.5	(0.06) 9.3	(0.57)
NHP	Pain 2.5	(0.39) 3.9	(0.44) −2.5	(0.76) −6.1	(0.39)
NHP	Emotional	reactions 2.3	(0.38) 6.6	(0.16) 2.3	(0.70) 5.3	(0.69)
NHP	Sleep −0.3	(0.94) 6.3	(0.37) 13.8	(0.22) 21.5	(0.12)
NHP	Social	isolation 1.3	(0.38) 1.9	(0.62) −2.4	(0.36) 1.0	(0.85)
NHP	Physical	mobility 7.6	(0.06) 9.3	(0.21) 12.0	(0.16) 15.6	(0.15)
VAS −5.7	(0.06) −4.7	(0.33) −6.7	(0.34) −3.7	(0.63)
